Skip to content

The clinical efficacy research for the treatment among intravenous unfractionated heparin, two antiplatelet agents (clopidogrel and aspirin)and single antiplatelet agent (aspirin) to acute cerebral infarction and transient ischemic attack(TIA).

The clinical efficacy research for the treatment among intravenous unfractionated heparin, two antiplatelet agents (clopidogrel and aspirin)and single antiplatelet agent (aspirin) to acute cerebral infarction and transient ischemic attack(TIA).

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-OPN-16007931
Enrollment
Unknown
Registered
2016-02-16
Start date
2016-11-01
Completion date
Unknown
Last updated
2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute cerebral infarction, transient ischemic attack

Interventions

The unfractionated heparin Group:Daily given unfractionated 100mg by intravenous, continuous 5-7 days.Then the operator give patients with aspirin 200mg/day for 7 days. 15-90 days give aspirin 100mg/d
Dual antiplatelet drugs therapy group (aspirin plus clopidogrel):The operator give patient with clopidogrel 300 mg +aspirin 100mg on the first day
2-14 days give Dual Antiplatelet Therapy: clopidogrel 75 mg/d +aspirin 100 mg/d .15-90 days give aspirin 100mg/day.
Single antiplatelet drug therapy group (aspirin):The operator give patient with aspirin 300mg on the first day
2-14 days give aspirin 200 mg/d .15-90 days give aspirin 100mg/day.

Sponsors

The Department of Neurology, The Second Affiliated Clinical Hospital Of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Aged 18 to 85 years old; The onset time: within 7 days of admission; Diagnosis of cerebral infarction TIA (NIHSS score <=16 points); Removal of intracranial hemorrhage with head CT; Signed informed consent; Choose better compliance patients, in order to complete test and observation.

Exclusion criteria

Exclusion criteria: Previous intracranial hemorrhage, including suspected subarachnoid hemorrhage; The history of traumatic brain injury in the last 3 months; There were gastrointestinal or urinary tract bleeding in the past 3 weeks;Over the past 2 weeks to carry out a large surgery; in the past 1 weeks, there is a puncture in the artery which is not easy to stop bleeding; Physical examination revealed evidence of active bleeding or trauma (such as fractures); Severe heart, liver, kidney and other important organ function damage and blood disease; Anticoagulation, thrombolysis and fibrinolysis were carried out within 24 hours; There was a history of gout,asthma, peptic ulcer and heparin or anti platelet aggregation drug allergy or any other history of allergies; Blood pressure: systolic blood pressure >180mmHg, or diastolic blood pressure >100mmHg; Abnormal coagulation function (such as APTT abnormalities and platelet <100*10^9/L, etc.); Pregnancy and lactation; Cardioembolism.

Design outcomes

Primary

MeasureTime frame
The NIHSS score;The SSS score;The general condition and mental state assessment;The Ranking Score;The ABCD2 Score;The attack times of TIA;Episode duration of TIA;Whether the progression of cerebral infarction;

Secondary

MeasureTime frame
The treatment time of stable condition and improved;The finish event evaluation;Bleeding events evaluation;The finish event evaluation;Bleeding events evaluation;

Countries

China

Contacts

Public ContactFu Jin

The Department of Neurology, The Second Affiliated Clinical Hospital of Harbin Medical University

fujin6677@126.com+86 13039998769

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026